The poor response of existing treatnnent options for unresectable pancreatic cancer is the result of a subset of cancer cells exhibiting chemoresistance. Evidence has shown that the capacity of a tumor to grow and propagate is dependent on this small subset of cells, identified as pancreatic cancer stem (or stem-like) cells (CSCs). Due to their vital role in tumor maintenance and the formation of metastases, CSCs are integral targets to treat pancreatic cancer, as current therapeutic regimens cannot effectively treat this cell population because of its intrinsically resistant nature. Adenovirus (Ad)-based oncolytic viruses have unique advantages for targeting and eradicating pancreatic CSCs along with inclusively targeting the general pancreatic cancer cell population and thereby represent a promising novel therapeutic strategy. Ad replication specificity can be achieved by placing viral replication genes under the control of tumor-specific promoters, thereby generating conditionally replicative adenoviruses (CRAds). The keys to developing a pancreatic cancer CRAd that inclusively targets CSCs are: 1) effective transduction and 2) replication specificity of pancreatic cancer cells and CSCs. We have developed innovative strategies and breakthrough technologies which can be rapidly applied for designing such CRAds. Our advanced infectivity enhancement strategies allow efficient transduction of pancreatic cancer cells and CSCs. To confer replication specificity, we have developed the CXCR4 promoter as a CRAd replication control element. CXCR4 expression Is a signature of pancreatic cancer and CSCs. SA 1: To construct infectivity-enhanced, CXCR4 promoter controlled CRAds for pancreatic cancer, inclusively targeting pancreatic CSCs. SA 2: To validate the efficacy of CRAds with in vitro models of chemoresistant pancreatic CSCs. SA 3: To demonstrate efficacious targeting and replication of CXCR4 CRAds with in vivo models of pancreatic cancer. SA 4: To validate the efficacy and specificity of pancreatic CSC-targeted CRAds with primary CSCs derived from human patient tumors. Development of an effective therapy for the advanced pancreatic cancer Is predicated on efficiently targeting and eradicating pancreatic CSCs, which represent the chemoresistant nature of this disease. The strategy proposed herein, of exploiting CRAd agents based on the CXCR4 axis to inclusively target pancreatic CSCs offers a promising treatment approach. On the basis of these studies, we will thus understand the direct utility of our novel system for clinical application and will facilitate a rapid clinical translation. We will submit an IND application concurrently with this proposal to rapidly translate the agents herein for clinical trial.

Public Health Relevance

Development of an effective therapy for the treatment of advanced pancreatic cancer is predicated on efficiently targeting and eradicating pancreatic cancer stem cells (CSCs), which represent the chemoresistant nature of this disease. Recent advances in adenovirus (Ad)-based oncolytic virus design allow the application of Ad vectors as a therapeutic strategy to efficiently target and eradicate pancreatic nSCs therehv imnrnvina the efficacv nf nannreatic cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101955-09
Application #
8528358
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$151,065
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hwang, Chang-Il; Boj, Sylvia F; Clevers, Hans et al. (2016) Preclinical models of pancreatic ductal adenocarcinoma. J Pathol 238:197-204
Kim, Harrison; Samuel, Sharon; Lopez-Casas, Pedro et al. (2016) SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther 15:680-8
Baker, Lindsey A; Tiriac, Hervé; Clevers, Hans et al. (2016) Modeling pancreatic cancer with organoids. Trends Cancer 2:176-190
Tzou, Ywh-Min; Bailey, Sarah K; Yuan, Kaiyu et al. (2016) Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer. Bioorg Med Chem Lett 26:1237-44
Biffi, G; Öhlund, D; Tuveson, D (2016) Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. Cell Death Differ 23:1265-6
Chio, Iok In Christine; Jafarnejad, Seyed Mehdi; Ponz-Sarvise, Mariano et al. (2016) NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Cell 166:963-76
Schultz, Matthew J; Holdbrooks, Andrew T; Chakraborty, Asmi et al. (2016) The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. Cancer Res 76:3978-88
Nam, Ki-Hwan; Kim, Peter; Wood, David K et al. (2016) Multiscale Cues Drive Collective Cell Migration. Sci Rep 6:29749
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Ho, Yen-Yi; Starr, Timothy K; LaRue, Rebecca S et al. (2016) Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen. BMC Med Genomics 9:16

Showing the most recent 10 out of 152 publications